期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小儿肺动脉高压的靶向药物治疗进展 被引量：4

下载PDF
导出
摘要 肺动脉高压（PAH）是发病率低但危及生命的疾病。疾病特点是肺血管床进行性的结构改变,随后肺血管阻力（PVR）和肺动脉压增加,最终导致右心衰和死亡。发病机制不完全明确,主要为血管收缩、炎症反应、结构重塑、凋亡抵抗、原位血栓和血管活性调节失衡的联合作用。内源性缩血管因子包括血栓素A2和内皮素-1（ET-1）增加,血管扩张剂及抗增生性血管活性介质如前列环素,一氧化氮氧化氮（NO）减少[1].
作者 黄波 杨雪红
机构地区 南京军区福州总医院第一附属医院儿科
出处 《实用医学杂志》 CAS 北大核心 2015年第18期3106-3108,共3页 The Journal of Practical Medicine
关键词 肺动脉高压 前列环素 靶向药物治疗 原位血栓 肺血管床 肺血管阻力 肺动脉压 疾病特点 右心衰 血管扩张剂
分类号 R725.4 [医药卫生—儿科]
  • 相关文献

参考文献23

  • 1Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling I J]. JAmColl Cardiol, 2009,54( 1 Suppl) : S10-9. 被引量：1
  • 2Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children[J ].Paediatr Drugs. 2014, 16( 1 ) :43-65. 被引量：1
  • 3Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Servicefor Children 2001-2006[J].Heart, 2009 , 95(4) :312-317. 被引量：1
  • 4Rosenzweig EB, Feinstein JA, Humpl T, et al. Pulmonary arterial hypertension in children: diagnostic work up and challenges[J] .Prog Pediatr Cardiol. 2009,27( 1 ) : 7-11. 被引量：1
  • 5Maxey DM, Ivy DD, Ogawa MT , et al. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients [J]. Pediatr Cardiol, 2013,34 (7) : 1628- 1636. 被引量：1
  • 6Khan AS, Sheikh Z, Khan S, et al. Viagra deafness- sensorineural hearing loss and phosphodiesterase-5 inhibitors [ J ]. Laryng pe, 2011,121 (5): 1049-1054. 被引量：1
  • 7郭玮,张焕改,谷惠芳,王敬群,杨柳.枸橼酸西地那非治疗新生儿肺动脉高压50例[J].医药导报,2013,32(5):616-618. 被引量：15
  • 8陈玲,张炼,李文斌.不同剂量西地那非治疗新生儿肺动脉高压的疗效[J].华中科技大学学报（医学版）,2012,41(2):210-213. 被引量：41
  • 9Takatsuki S, Calderhank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension [J]. Pediatr Cardiol, 2012,33 (5) : 683-688. 被引量：1
  • 10Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokineties, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension [J]. Pediatr Pulmonol, 2013,48 ( 1 ) : 27-34. 被引量：1

二级参考文献44

  • 1曾嵘,庄建,岑坚正,陈欣欣,熊卫萍,朱卫中.枸橼酸西地那非治疗心脏手术后肺动脉高压的临床研究[J].中华心血管病杂志,2005,33(10):916-919. 被引量：28
  • 2杜军保,石云.新生儿持续肺动脉高压[J].中国新生儿科杂志,2006,21(3):181-184. 被引量：19
  • 3童凡,杜立中,施丽萍.西地那非与前列地尔治疗先天性心脏病术后肺动脉高压的疗效对比[J].中华急诊医学杂志,2006,15(11):1002-1005. 被引量：11
  • 4Raja S G,Danton M D,Macarthur K J,et al.Treatment of pulmonary arterial hypertension with sildenafil:from pathophysiology to clinical evidence[J].J Cardiothorac Vasc Anesth,2006,20(5):722-735. 被引量：1
  • 5Namachivayam P,Theilen U,Butt W W,et al.Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children[J].Am J Respir Crit Care Med,2006,174(9):1042-1047. 被引量：1
  • 6Attino T M,Malatino L S,Maxwell S R,et al.Phosphodies-terase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients[J].J Hypertens,2008,26(3):501-507. 被引量：1
  • 7Krishnan U.Management of pulmonary arterial hypertensi-on in the neonatal unit[J].Cardiol Rev,2010,18(2):73-75. 被引量：1
  • 8Leuchte H H,Schwaiblmair M,Baumgartner R A,et al.Hem-odynamic response to sildenafil,nitric oxide,and iloprost in primary pulmonary hypertension[J].Chest 2004,125(2):580-586. 被引量：1
  • 9Michelakis E D,Tymchak W,Noga M,et al.Long-term treatment with oral silednafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension[J].Circulation,2003,108(17):2066-2069. 被引量：1
  • 10de Visser Y P,Walther F J,Laghmaniel H,et al.Sildenafil attenuates pulmonary inflammation and fibrin deposition,mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury[J].Respir Res,2009,10:30. 被引量：1

共引文献63

同被引文献62

  • 1DENTON CP. Systemic sclerosis: from pathogenesis to targeted therapy [J]. Clinical and experimental rheumatology, 2015,33 (4 Suppl 92) :S3-7. 被引量：1
  • 2LEFEVRE G, DAUCHET L, HACHULLA E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis [J]. Arthritis and rheumatism, 2013,65(9) :2412-2423. 被引量：1
  • 3VAN DEN HOOGEN F, KHANNA D, FRANSEN J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative [J]. Annals of the rheumatic diseases, 2013,72( 11 ) : 1747-1755. 被引量：1
  • 4Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events : final report of the pooling project. The pooling project research group [ J ]. J Chronic Dis, 1978,31 (4) : 201-306. 被引量：1
  • 5CUTOLO M, SULLI A, PIZZORNI C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis [ l ]. J Rheumatol, 2000,27 (1 ):155-160. 被引量：1
  • 6OZANTURK E, UCAR ZZ, VAROL Y, et al. Urinary uric acid excretion as an indicator of severe hypoxia and mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease [J]. Revista portuguesa de pneumologia, 2016,22(1) : 18-26. 被引量：1
  • 7DIMITROULAS T, GIANNAKOULAS G, DIMITROULA H, et al. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study [J]. Rheumatology international, 2011,31 (2) : 263-267. 被引量：1
  • 8GIGANTE A, BARBANO B, BARILARO G, et al. Serum uric acid as a marker of microvascular damage in systemic sclerosis patients [J]. Microvascular Res, 2016, (106) : 39-43. 被引量：1
  • 9GASHOUTA M A, HUMBERT M, HASSOUN P M. Update in systemic sclerosis-associated pulmonary arterial hypertension [J]. Presse medicale (Paris, France: 1983), 2014,43 (10 Pt 2): e293-304. 被引量：1
  • 10KHERBECK N, TAMBY M C, BUSSONE G, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension [J]. Clinical reviews in allergy & immunology, 2013,44( 1 ) :31-38. 被引量：1

引证文献4

二级引证文献19

实用医学杂志
2015年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部